Additionally, we discovered for the first time in HCC that DNMT3L can reduce the promoter methylation of cysteine dioxygenase 1 (CDO1) by competitively inhibiting DNMT3A, thereby exerting its anticancer function through an unconventional pathway that contradicts the prevailing view. This evidence concerns the gene DNMT3L and hepatocellular carcinoma.